ACC/AHA指南在非糖尿病欧洲人他汀一级预防中优于ESC/EAS指南
在哥本哈根一般人群研究的44 889名40-75岁无ASCVD、糖尿病且未使用他汀的个体中,比较ACC/AHA与ESC/EAS指南的他汀一级预防资格。US-PCE预测任何ASCVD事件比值1.2,European-SCORE预测致死性ASCVD比值5.0。ACC/AHA Class I推荐他汀资格42% vs ESC/EAS 6%,敏感性增益大于特异性损失。
要点
- US-PCE对任何ASCVD校准良好,European-SCORE对致死性ASCVD高估5倍。
- ACC/AHA Class I他汀资格42% vs ESC/EAS 6%,敏感性增益大于特异性损失。
- US-PCE风险5%与European-SCORE风险1.4%的敏感性和特异性相似。
核心结论
- ACC/AHA指南在非糖尿病欧洲人ASCVD一级预防中优于ESC/EAS指南,能更准确地将他汀治疗分配给获益者。
研究设计与样本
- 基于哥本哈根一般人群研究,纳入2003-09年招募的44 889名40-75岁无ASCVD、糖尿病且未使用他汀的个体,随访至2014年。
主要发现
- US-PCE预测任何ASCVD的预测-观察事件比为1.2,European-SCORE预测致死性ASCVD的预测-观察事件比为5.0。
- ACC/AHA Class I推荐他汀资格42% vs ESC/EAS 6%,敏感性增益任何ASCVD +62%、致死性ASCVD +76%,特异性损失任何ASCVD -35%、致死性ASCVD -36%。
- US-PCE风险5%与European-SCORE风险1.4%的敏感性和特异性相似,US-PCE风险7.5%与European-SCORE风险2.4%相似。
关键数值与推荐
- ACC/AHA Class I推荐他汀资格42% vs ESC/EAS 6%。
- US-PCE风险5%与European-SCORE风险1.4%的敏感性和特异性相似。
- US-PCE风险7.5%与European-SCORE风险2.4%相似。
临床怎么用
- 在非糖尿病欧洲人群中,使用ACC/AHA指南评估他汀一级预防资格可提高敏感性,但需接受特异性降低。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: We compared the 2013 American College of Cardiology/American Heart Association (ACC/AHA) and the 2016 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines on prevention of atherosclerotic cardiovascular disease (ASCVD) using different risk prediction models [US Pooled Cohort Equations (US-PCE for any ASCVD) and European Systematic COronary Risk Evaluation system (European-SCORE for fatal ASCVD)] and different statin eligibility criteria. METHODS AND RESULTS: We examined 44 889 individuals aged 40-75 recruited in 2003-09 in the Copenhagen General Population Study, all free of ASCVD, diabetes, and statin use at baseline. We detected 2217 any ASCVD events and 199 fatal ASCVD events through 2014. The predicted-to-observed event ratio was 1.2 using US-PCE for any ASCVD and 5.0 using European-SCORE for fatal ASCVD. The US-PCE, but not the European-SCORE, was well-calibrated around decision thresholds for statin therapy. For a Class I recommendation, 42% of individuals qualified for statins using the ACC/AHA guidelines vs. 6% with the ESC/EAS guidelines. Using ACC/AHA- vs. ESC/EAS-defined statin eligibility led to a substantial gain in sensitivity (+62% for any ASCVD and +76% for fatal ASCVD) with a smaller loss in specificity (-35% for any ASCVD and -36% for fatal ASCVD). Similar differences between the ACC/AHA and ESC/EAS guidelines were found for men and women separately, and for Class IIa recommendations. The sensitivity and specificity of a US-PCE risk of 5% were similar to those of a European-SCORE risk of 1.4%, whereas a US-PCE risk of 7.5% was similar to a European-SCORE risk of 2.4%. CONCLUSIONS: The ACC/AHA guidelines were superior to the ESC/EAS guidelines for primary prevention of ASCVD, that is, for accurately assigning statin therapy to those who would benefit.
引用
- Mortensen MB, Nordestgaard BG, Afzal S, et al. ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen General Population Study. Eur Heart J. 2017. PMID: 28363217. doi:10.1093/eurheartj/ehw426
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。